Status:
COMPLETED
Oral Iron Supplementation in Pulmonary Hypertension
Lead Sponsor:
The Cleveland Clinic
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
The purpose of this study is to investigate the effects of iron supplementation in patients with pulmonary arterial hypertension and iron deficiency.
Detailed Description
Pulmonary arterial hypertension (PAH) is a chronic disease associated with upregulation of hypoxia inducible-factor-1alpha (HIF-1alpha) and functional iron deficiency. The investigators are proposing ...
Eligibility Criteria
Inclusion
- age 21 and older
- diagnosis of idiopathic pulmonary arterial hypertension
- iron deficiency (transferrin saturation \<20% and serum ferritin \< 100 ug/l)
Exclusion
- active infection, malignancy, or bleeding
- hemochromatosis
- chronic inflammatory or autoimmune disease
- currently taking experimental/study medications, erythropoietin, iron supplementation, or immunosuppressants
- allergy to iron
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01446848
Start Date
January 1 2012
End Date
August 1 2014
Last Update
August 12 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195